npj Regenerative Medicine (Sep 2021)

Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS

  • Ashok K. Shetty,
  • Padmashri A. Shetty,
  • Gabriele Zanirati,
  • Kunlin Jin

DOI
https://doi.org/10.1038/s41536-021-00161-z
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 3

Abstract

Read online

Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional phase II/III trials are required to validate the efficacy of MSCs to improve the survival of COVID-19 patients with ARDS. Future studies also need to assess the efficacy of MSCs to prevent long COVID.